UNDERWRITING AGREEMENTUnderwriting Agreement • August 10th, 2020 • Scopus BioPharma Inc. • Pharmaceutical preparations • New York
The undersigned, Scopus BioPharma Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) with The Benchmark Company, LLC (hereinafter the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
Scopus BioPharma Inc. New York, New York 10170Letter Agreement • August 10th, 2020 • Scopus BioPharma Inc. • Pharmaceutical preparations • New York
This letter agreement (Agreement) outlines the terms on which Kilinwata Investments Pty Ltd, as trustee for the Life Science Portfolio Managers Trust (Kilinwata), has agreed to make available the services of Paul Hopper (Hopper) to act as the Co-Chairman of Scopus BioPharma Inc. (Company) following the closing (Closing) as defined in the Conditional Stock Purchase Agreement dated June 8, 2020 by, between and among the Company, Biosciences Oncology Pty. Ltd., Hopper and the selling shareholders parties thereto.
